Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 1/2018

Open Access 01-01-2018 | Magnetic Resonance

Ferumoxytol-enhanced magnetic resonance angiography for the assessment of potential kidney transplant recipients

Authors: Sokratis Stoumpos, Martin Hennessy, Alex T. Vesey, Aleksandra Radjenovic, Ram Kasthuri, David B. Kingsmore, Patrick B. Mark, Giles Roditi

Published in: European Radiology | Issue 1/2018

Login to get access

Abstract

Objectives

Traditional contrast-enhanced methods for scanning blood vessels using magnetic resonance imaging (MRI) or CT carry potential risks for patients with advanced kidney disease. Ferumoxytol is a superparamagnetic iron oxide nanoparticle preparation that has potential as an MRI contrast agent in assessing the vasculature.

Methods

Twenty patients with advanced kidney disease requiring aorto-iliac vascular imaging as part of pre-operative kidney transplant candidacy assessment underwent ferumoxytol-enhanced magnetic resonance angiography (FeMRA) between December 2015 and August 2016. All scans were performed for clinical indications where standard imaging techniques were deemed potentially harmful or inconclusive. Image quality was evaluated for both arterial and venous compartments.

Results

First-pass and steady-state FeMRA using incremental doses of up to 4 mg/kg body weight of ferumoxytol as intravenous contrast agent for vascular enhancement was performed. Good arterial and venous enhancements were achieved, and FeMRA was not limited by calcification in assessing the arterial lumen. The scans were diagnostic and all patients completed their studies without adverse events.

Conclusions

Our preliminary experience supports the feasibility and utility of FeMRA for vascular imaging in patients with advanced kidney disease due for transplant listing, which has the advantages of obtaining both arteriography and venography using a single test without nephrotoxicity.

Key Points

• Evaluation of vascular disease is important in planning kidney transplantation.
• Standard vascular imaging methods are often problematic in kidney disease patients.
• FeMRA has the advantage of arteriography and venography in a single test.
• FeMRA is safe and non-nephrotoxic.
• FeMRA is not limited by arterial calcification.
Literature
1.
Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM, Ellis JH (2013) Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material. Radiology 267:94–105CrossRefPubMedPubMedCentral
2.
Parfrey PS, Griffiths SM, Barrett BJ et al (1989) Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320:143–149CrossRefPubMed
3.
Collidge TA, Thomson PC, Mark PB et al (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245:168–175CrossRefPubMed
4.
Prince MR, Zhang HL, Chabra SG, Jacobs P, Wang Y (2003) A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. J Xray Sci Technol 11:231–240PubMed
5.
Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J (2014) A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol: CJASN 9:705–712CrossRefPubMedPubMedCentral
6.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470CrossRefPubMed
7.
Andres A, Revilla Y, Ramos A et al (2003) Helical computed tomography angiography is the most efficient test to assess vascular calcifications in the iliac arterial sector in renal transplant candidates. Transplant Proc 35:1682–1683CrossRefPubMed
8.
Wilhelm-Leen E, Montez-Rath ME, Chertow G (2017) Estimating the risk of radiocontrast-associated nephropathy. J Am Soc Nephrol 28:653–659CrossRefPubMed
9.
McDonald JS, McDonald RJ, Comin J et al (2013) Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology 267:119–128CrossRefPubMed
10.
McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE (2014) Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology 271:65–73CrossRefPubMed
11.
McDonald RJ, McDonald JS, Carter RE et al (2014) Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. Radiology 273:714–725CrossRefPubMed
12.
McDonald RJ, McDonald JS, Bida JP et al (2013) Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology 267:106–118CrossRefPubMed
13.
McDonald JS, McDonald RJ, Lieske JC et al (2015) Risk of acute kidney injury, dialysis, and mortality in patients with chronic kidney disease after intravenous contrast material exposure. Mayo Clin Proc 90:1046–1053CrossRefPubMedPubMedCentral
14.
Bremerich J, Bilecen D, Reimer P (2007) MR angiography with blood pool contrast agents. Eur Radiol 17:3017–3024CrossRefPubMed
15.
Ersoy H, Jacobs P, Kent CK, Prince MR (2004) Blood pool MR angiography of aortic stent-graft endoleak. AJR Am J Roentgenol 182:1181–1186CrossRefPubMed
16.
Bashir MR, Bhatti L, Marin D, Nelson RC (2015) Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging: JMRI 41:884–898CrossRefPubMed
17.
Storey P, Lim RP, Chandarana H et al (2012) MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Investig Radiol 47:717–724CrossRef
18.
Fananapazir G, Marin D, Suhocki PV, Kim CY, Bashir MR (2014) Vascular artifact mimicking thrombosis on MR imaging using ferumoxytol as a contrast agent in abdominal vascular assessment. J Vasc Interv Radiol: JVIR 25:969–976CrossRefPubMed
19.
20.
Airy M, Mandayam S, Mitani AA et al (2015) Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc Eur Ren Assoc 30:2068–2075CrossRef
21.
Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF (2014) A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol 89:646–650CrossRefPubMedPubMedCentral
22.
Vadhan-Raj S, Strauss W, Ford D et al (2014) Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol 89:7–12CrossRefPubMed
23.
Auerbach M, Strauss W, Auerbach S, Rineer S, Bahrain H (2013) Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Am J Hematol 88:944–947CrossRefPubMed
24.
Schiller B, Bhat P, Sharma A (2014) Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther 36:70–83CrossRefPubMed
25.
Bircher AJ, Auerbach M (2014) Hypersensitivity from intravenous iron products. Immunol Allergy Clin N Am 34:707–723, x-xi CrossRef
26.
Sigovan M, Gasper W, Alley HF, Owens CD, Saloner D (2012) USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. Radiology 265:584–590CrossRefPubMedPubMedCentral
27.
Hedgire SS, McDermott S, Wojtkiewicz GR, Abtahi SM, Harisinghani M, Gaglia JL (2014) Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent. Int J Nanomedicine 9:2101–2107PubMedPubMedCentral
28.
Corwin MT, Fananapazir G, Chaudhari AJ (2016) MR angiography of renal transplant vasculature with ferumoxytol: comparison of high-resolution steady-state and first-pass acquisitions. Acad Radiol 23:368–373CrossRefPubMed
29.
Bashir MR, Jaffe TA, Brennan TV, Patel UD, Ellis MJ (2013) Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent. Transplantation 96:91–96CrossRefPubMed
30.
Fananapazir G, Bashir MR, Corwin MT, Lamba R, Vu CT, Troppmann C (2017) Comparison of ferumoxytol-enhanced MRA with conventional angiography for assessment of severity of transplant renal artery stenosis. J Magn Reson Imaging: JMRI 45:779–785CrossRefPubMed
31.
Bashir MR, Mody R, Neville A et al (2014) Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases. J Magn Reson Imaging: JMRI 40:113–118CrossRefPubMed
32.
Nayak AB, Luhar A, Hanudel M et al (2015) High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. Pediatr Nephrol 30:515–521CrossRefPubMed
33.
Luhar A, Khan S, Finn JP et al (2016) Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Pediatr Radiol 46:1332–1340CrossRefPubMed
34.
Hedgire SS, Mino-Kenudson M, Elmi A, Thayer S, Fernandez-del Castillo C, Harisinghani MG (2014) Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation. Int J Nanomedicine 9:1891–1896CrossRefPubMedPubMedCentral
35.
Klenk C, Gawande R, Uslu L et al (2014) Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncol 15:275–285CrossRefPubMed
Metadata
Title
Ferumoxytol-enhanced magnetic resonance angiography for the assessment of potential kidney transplant recipients
Authors
Sokratis Stoumpos
Martin Hennessy
Alex T. Vesey
Aleksandra Radjenovic
Ram Kasthuri
David B. Kingsmore
Patrick B. Mark
Giles Roditi
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 1/2018
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-4934-5

Other articles of this Issue 1/2018

European Radiology 1/2018 Go to the issue

Neuro

MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis

Ultrasound

Development of a reliable simulation-based test for diagnostic abdominal ultrasound with a pass/fail standard usable for mastery learning

Gastrointestinal

Detection of small-bowel tumours with CT enteroclysis using carbon dioxide and virtual enteroscopy: A preliminary study

Urogenital

Assessment of acute kidney injury with T1 mapping MRI following solid organ transplantation

Computed Tomography

Radiation dose reduction for CT assessment of urolithiasis using iterative reconstruction: A prospective intra-individual study

Ultrasound

Anterolateral ligament injuries in knees with an anterior cruciate ligament tear: Contribution of ultrasonography and MRI